Journals / Turkish Journal of Cancer / 2001 / Cilt: 31 - Sayı: 2

Stereologic estimation of mean nuclear volume in invasive ductal carcinoma of the breast: İt's impact on prognosis

Pages
47–56
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Stereologic estimation of mean nuclear volume in invasive ductal carcinoma of the breast: İt's impact on prognosis

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Stereologic estimation of mean nuclear volume in invasive ductal carcinoma of the breast: İt's impact on prognosis
📊
Key Findings & Data:Stereologic estimation of mean nuclear volume in invasive ductal carcinoma of the breast: İt's impact on prognosis
💡
Conclusion & Impact:Stereologic estimation of mean nuclear volume in invasive ductal carcinoma of the breast: İt's impact on prognosis
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Stereologic estimation of mean nuclear volume in invasive ductal carcinoma of the breast: İt's impact on prognosis

🔖

Cite This Article

ELPEK, G. Ö., SAKA, O., KARAVELİ, Ş., ÖZGÜR, M. A. (2022). Stereologic estimation of mean nuclear volume in invasive ductal carcinoma of the breast: İt's impact on prognosis. Turkish Journal of Cancer, Cilt: 31 - Sayı: 2, 47–56. https://ajindex.com/articles/601305

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Landis SH, Taylor M, Bolden S, et al. Cancer statistics,1998. CA Cancer J Clin 1998;48:6-29
  2. Bonadonna G, Valagussa P, Rossi A, et al. Ten years experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985;5:95-115
  3. Bonadonna G, Valagussa P, Rossi A, et al. Adjuvant CMF chemotherapy in operable breast cancer: ten years later. Lancet 1985;2:976-7
  4. Early breast cancer trialists’ collaborative group. Effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28896 women. N Engl J Med 1988;319:1681-92
  5. Isola J, Visakorpi T, Holli K, et al. Association of overexpression of tumor suppressor proteins p53 with rapid proliferation and poor prognosis in nodenegative breast cancer patients. J Natl Cancer Inst 1992;84:1109-14
  6. Toi M, Osaki A, Yamada H, et al. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 1991;27:977-80
  7. Altomaa S, Lipponen P, Syrjannen K. Nucleolar organiser regions related to morphometry, flow cytometry, sex steroid receptor content, tumour histology and prognosis in female breast cancer. Path Res Pract 1993;189:416-21
  8. Eskelinen M, Lipponen P, Papinaho S, et al. DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer. Int J Cancer 1992;51:555-61
  9. Toikkanen S, Joensuu H. Prognostic factors and long term survival in breast cancer in a defined urban population. APMIS 1990;98:1005-14
  10. Baak JPA, van Dop H, Kurver PHJ, et al. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985;56:374-82
  11. Uyterlinde AM, Baak JPA, Schipper NW, et al. Further evaluation of the prognostic value of morphometric and flow cytometric parameters in breast cancer patients with long follow-up. Int J Cancer 1990;45:1-7
  12. Laroye GJ, Minkin S. The impact of mitotic index on predicting outcome in breast carcinoma: a comparison of different counting methods in patients with different lymph node status. Mod Pathol 1991;4:456-60
  13. Landis SH, Taylor M, Bolden S, et al. Cancer statistics,1998. CA Cancer J Clin 1998;48:6-29
  14. Bonadonna G, Valagussa P, Rossi A, et al. Ten years experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985;5:95-115
  15. Bonadonna G, Valagussa P, Rossi A, et al. Adjuvant CMF chemotherapy in operable b